SELLAS Life Sciences Grou... (SLS)
SELLAS Life Sciences Statistics
Share Statistics
SELLAS Life Sciences has 90.85M shares outstanding. The number of shares has increased by 57.3% in one year.
| Shares Outstanding | 90.85M |
| Shares Change (YoY) | 57.3% |
| Shares Change (QoQ) | 29.08% |
| Owned by Institutions (%) | 9.95% |
| Shares Floating | 88.96M |
| Failed to Deliver (FTD) Shares | 37.24K |
| FTD / Avg. Volume | 1.45% |
Short Selling Information
The latest short interest is 8.61M, so 12.23% of the outstanding shares have been sold short.
| Short Interest | 8.61M |
| Short % of Shares Out | 12.23% |
| Short % of Float | 12.52% |
| Short Ratio (days to cover) | 14.07 |
Valuation Ratios
The PE ratio is -20.61 and the forward PE ratio is -2.3. SELLAS Life Sciences's PEG ratio is 0.31.
| PE Ratio | -20.61 |
| Forward PE | -2.3 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 67.25 |
| P/FCF Ratio | -17.98 |
| PEG Ratio | 0.31 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for SELLAS Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.11.
| Current Ratio | 1.72 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.06M |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -16.79% in the last 52 weeks. The beta is 2.44, so SELLAS Life Sciences's price volatility has been higher than the market average.
| Beta | 2.44 |
| 52-Week Price Change | -16.79% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 40.56 |
| Average Volume (20 Days) | 2.58M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -31.51M |
| Net Income | -30.88M |
| EBITDA | -31.51M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 13.99M in cash and 1M in debt, giving a net cash position of 12.98M.
| Cash & Cash Equivalents | 13.99M |
| Total Debt | 1M |
| Net Cash | 12.98M |
| Retained Earnings | -248.13M |
| Total Assets | 19.43M |
| Working Capital | 6.82M |
Cash Flow
In the last 12 months, operating cash flow was -35.4M and capital expenditures 0, giving a free cash flow of -35.4M.
| Operating Cash Flow | -35.4M |
| Capital Expenditures | 0 |
| Free Cash Flow | -35.4M |
| FCF Per Share | -0.06 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SLS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Nov 8, 2019. It was a backward split with a ratio of 1:50.
| Last Split Date | Nov 8, 2019 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -16.9 |
| Piotroski F-Score | 1 |